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Electrochemical parametersIn our continued search for novel trypanocidal compounds, twenty-six derivatives of para- and ortho-
naphthoquinones coupled to 1,2,3-triazoles were synthesized. These compounds were evaluated against
the infective bloodstream form of Trypanosoma cruzi, the etiological agent of Chagas disease. Compounds
17–24, 28–30 and 36–38 are described herein for the ﬁrst time. Three of these novel compounds (28–30)
were found to be more potent than the standard drug benznidazole, with IC50/24 h values between 6.8
and 80.8 lM. Analysis of the toxicity to heart muscle cells led to LC50/24 h of <125, 63.1 and 281.6 lM
for 28, 29 and 30, respectively. Displaying a selectivity index of 34.3, compound 30 will be further eval-
uated in vivo. The electrochemical properties of selected compounds were evaluated in an attempt to ﬁnd
correlations with trypanocidal activity, and it was observed that more electrophilic quinones were gen-
erally more potent.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Chagas disease (CD) is caused by the protozoan Trypanosoma
cruzi and affects approximately eight million individuals in Latin
America. Approximately 30–40% of these patients have, or will de-
velop, cardiomyopathy, digestive mega-syndromes, or both.1
Although vectorial (Triatoma infestans) and transfusional transmis-
sion of CD have declined steadily as a result of multinational initia-
tives,2 this disease can also be orally transmitted through the
ingestion of food or liquid contaminated with T. cruzi. This route
of transmission is the cause of regional outbreaks of acute infection
in areas devoid of domiciled insect vectors.3 Several outbreaks of
severe acute CD, each numbering in the hundreds of cases, have
been reported in the Amazon Region in recent decades.4 Most of
these outbreaks were the result of oral transmission. The emer-gence of CD in non-endemic areas, such as North America and
Europe, is another major concern. This development is due to the
immigration of infected individuals and subsequent transmission
via the blood, organ transplantation and congenital routes.5,6 Other
challenges remaining to be overcome in the ﬁght against CD in-
clude the development of sustainable public health policies, vector
control strategies and educational approaches.7,8
CD is characterized by a short acute phase deﬁned by patent
parasitemia followed by a long and progressive chronic phase.
Up to 40–50% of chronically infected patients develop progressive
cardiomyopathy, motility disturbances of the esophagus and colon,
or all of these symptoms. CD is the most severe parasitic infection
of the heart, which is the organ most often affected in chronic
patients.1 The available chemotherapy for CD is not satisfactory
and depends on two nitroheterocyclic agents: the 5-nitrofuran nif-
urtimox and the 2-nitroimidazole benznidazole. These compounds
are effective against acute infections, but they show poor activity
in the later chronic phase. These drugs also cause severe off-target
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must be applied in long-term therapy. These drawbacks justify the
urgent effort to identify better drugs for the treatment of CD.9,10
Nearly all current drug development efforts for CD are in the pre-
clinical research phase, although Phase II clinical trials with the
antifungal drug posaconazole are underway in Latin America and
Spain. A ravuconazole prodrug is also undergoing Phase II studies
in Bolivia.11
Plants represent a vast reservoir of phytoconstituents and sec-
ondary metabolites that can be used as templates for the design
of semi-synthetic or synthetic compounds. This approach can lead
to the discovery of new candidates for the treatment of neglected
tropical diseases with high therapeutic indices. Naphthoquinones
account for the majority of naturally occurring naphthalenes,12 dis-
playing an assortment of substituents over a variety of structural
motifs. They act as vital links in the electron transport chains of
metabolic pathways and participate in multiple biologically rele-
vant oxidative processes.13
Naphthoquinones are considered privileged scaffolds in
medicinal chemistry due to their structural properties and biolog-
ical activities,14 especially against tumor cells and pathogenic
protozoa.15 We have recently described the synthesis and trypan-
ocidal and leishmanicidal activities of 1,2,3-triazoles based on
the lapachone scaffold.16,17a Modiﬁcation of the prototype b-
lapachone, as shown in Scheme 1, is a relevant strategy for the
development of novel bioactive compounds. The C-ring was
modiﬁed to afford nor-b-lapachone and b-lapachone derivatives
with pronounced activity against trypomastigote forms of
T. cruzi.16 Other derivatives can be prepared by modiﬁcation of
the redox centre and the C-ring, as described in Scheme 1: arylami-
no derivatives of nor-b-lapachone, imidazoles and oxiranes are
important examples of this strategy.16–18 Recently, nor-a-lapach-
one and a-lapachone derivatives were also prepared and shown
to have potent activity against promastigote forms of
antimony-sensitive and -resistant strains of Leishmania infantum
(syn. L. chagasi) and L. amazonensis.17a
Several studies have investigated and reported the electro-
chemical behavior of quinones. Some correlation has been demon-
strated between electrochemical parameters and disease states.19
The quinone/semiquinone/hydroquinone (Q/SQ/H2Q) triad is an
important component of many redox systems in biology. It is
a vital link in the transfer of electrons through cells and tissues
(Eqs. 1–3).20O
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Electrochemical techniques have been used extensively to
provide excellent insights into the modes of action of various
drugs, and these results can inspire the design of next-generation
therapeutics. This approach is particularly suitable for diseases
associated with cellular oxidative stress, which is a hallmark of
cancer.19–21 Electrochemistry experiments can provide data on
the fundamental thermodynamic and kinetic properties associated
with the reactions of quinones and reduced intermediates.
The versatility and functional diversity of quinones are due
primarily to the diverse mid-point potentials that are sensitive to
substituent effects, solvent and medium effects (hydrophilic/
lipophilic) and interactions with certain macromolecules (e.g.,
DNA and proteins). The electronic properties of quinones are inﬂu-
enced by substituent groups, hydrogen bonding (H-bonding),
hydrophobic and p-stacking interactions and conformational
effects. These factors act in tandem to stabilize or destabilize the
semiquinone radical (under aprotic conditions or during enzymatic
one-electron transfer). They can be correlated to the nature of the
anion radical that is formed in vivo or to the completely reduced
species (hydroquinones or modiﬁed derivatives).19b,21
In this context, we herein describe the synthesis of para- and
ortho- naphthoquinones bearing 1,2,3-triazole substituents, as well
as 1,2,3-triazoles derived from a-lapachone and nor-a-lapachone.
These compounds were evaluated for activity against trypo-
mastigote forms of T. cruzi. Electrochemical studies of selected
compounds are also presented.
Our synthetic rationale was to combine para and ortho quinoi-
dal moieties with heterocycles (Schemes 2–4). Derivatives of
N-phthalimide have been shown to have biological signiﬁcance,
including antibacterial,22 antiviral,23 anticancer24 and anti-
hepatitis activity.25 Based on the pharmacological importance of
phthalimide analogues, we synthesized hybrids of 1,4-naphthoqui-
none and N-phthalimide conjugated through an aminomethyl-
triazole linkage. The introduction of a second quinoidal moiety
was also accomplished (Scheme 4) in a hybrid approach to
duplicate the effect of the quinone. Finally, the importance of the
redox centre was analyzed by modifying the structure ofO
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ilar to phenazine derivatives (Scheme 5).2. Results and discussion
2.1. Chemistry
a-Lapachone and nor-a-lapachone-derived 1,2,3-triazoles were
synthesized as described previously (Scheme 2).17a Lapachol (1)
was used to prepare a-lapachone (2), which was subsequently
treated with N-bromosuccinimide in carbon tetrachloride, in thepresence of benzoyl peroxide, to provide 4-bromo-a-lapachone.
This bromide was reacted with sodium azide to yield 4-azido-a-
lapachone (3). The 1,2,3-triazoles 4-6 were then obtained from
Cu(I)-catalyzed reactions with the appropriate alkynes, following
the methodology described by Sharpless and co-workers
(Scheme 2).17b
Lapachol (1) was used to prepare nor-lapachol in two steps as
described previously.26 This derivative was treated with HCl/AcOH
to provide nor-a-lapachone (7). Conversion to 3-bromo-nor-a-
lapachone and reaction with sodium azide in dichloromethane
gave the corresponding azide 8, as described previously.17a Triazole
derivatives 9–12 were synthesized from quinone 8 (Scheme 2).
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para-naphthoquinones 13–26 (Scheme 3). A series of
N-phthalimidoalkylazides was initially prepared for the synthesis
of compounds 13–22. These intermediates were used in click
chemistry reactions with substituted 2-(prop-2-yn-1-ylamine)-
naphthoquinone to obtain the respective triazole compounds in
high yields. Compounds 23 and 24were prepared by the click reac-
tion among the respective quinone and 1-azido-3-nitrobenzene.
Final compounds were typically isolated as crystalline solids, and
all spectroscopic data were in accordance with the proposed struc-
tures shown in Scheme 3. Compounds 17–24 are described herein
for the ﬁrst time.
The last set of naphthoquinoidal compounds was synthesized
from the intermediate azide 27 that we have described previ-
ously.16a Naphthoquinones substituted with a terminal alkyne
had been synthesized previously. These compounds were sub-
jected to click chemistry conditions17b to prepare novel derivatives
28–30 as shown in Scheme 4. Nor-b-lapachone derivatives 28–30
were isolated in moderate yields as yellow and orange solids.
Known compounds 31–35,16a,d shown in Scheme 4, were includedto study their electrochemical properties in comparison with their
trypanocidal activity (vide infra).
Cu-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) is a well
established methodology using Cu(I) as source of catalysis.28 Here-
in, we described the synthesis of quinone-based 1,2,3-triazoles
using two reaction conditions, the most common using aqueous
conditions employing CuSO45H2O and sodium ascorbate as reduc-
ing agent and copper(I) iodide in acetonitrile. As recently described
by Meldal and Tornøe29 there is no obvious correlation between
method used and yield of reaction. In general, CuSO45H2O and so-
dium ascorbate is preferred due to ease of workup, while, in other
reactions, the copper(I) iodide can be used to improve the rate of
reaction. In this manuscript the classical methodology published
by Sharpless and co-workers17b was used preferentially. In the case
of low yields and long reaction time, copper(I) iodide in acetonitrile
or the same condition under ultrasound energy were used.
The phenyl substituted 1,2,3-triazole derived from
nor-b-lapachone (31) was described previously and was shown
to be sixfold more potent than the standard drug benznidazole
against trypomastigote forms of T. cruzi.16a Herein we describe
a b
c d
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Figure 1. Cyclic voltammograms of naphthoquinones 4, 6, 9, 16, 25, 26, 28, 30–35 (c = 1  103 mol L1). DMF/TBAP (0.1 mol L1), glassy carbon electrode, cathodic direction,
v = 50 mV.
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(Scheme 5). Our strategy was based on modifying the redox centre
of 31. We selected modiﬁcation reactions from previously pub-
lished studies on related b-lapachone derivatives, which showedpronounced activity against T. cruzi.16 Compound 31 was obtained
in ﬁve steps, in good overall yield, starting from lapachol (1).16a
Intermediate 31 reacted smoothly with ethane-1,2-diamine or
ortho-phenylenediamine in acetic acid30 to furnish compounds
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6342 E. B. T. Diogo et al. / Bioorg. Med. Chem. 21 (2013) 6337–634836 and 37 in excellent yields. Oxime 38 was prepared by reaction
of 31 with hydroxylamine in ethanol in the presence of TEA
(Scheme 5).31
The structures of novel compounds 17–24, 28–30 and 36–38
were determined by 1H, 13C NMR, and IR. The structures were fur-
ther characterized by comparing their spectroscopic data with
those of similar compounds known in the literature.16a,17a,18 Elec-
trospray ionization mass spectra and combustion analysis datawere also obtained. Crystals of 38 suitable for X-ray analysis were
obtained, and the structure was solved. ORTEP-3 projections are
shown in Figure 2, and these reveal the Z-stereochemistry.
2.2. Electrochemistry
In a typical measurement, cyclic voltammograms (CV) were re-
corded ﬁrst in aprotic medium (DMF + TBAP, 0.1 mol L1), at a scan
Table 1
Major electrochemical parameters of the quinones (c = 1  103 mol L1), in DMF/
TBAP, 0.1 mol L1, m = 50 mV s1
Compound Epc1 (V) Eredox (V) Epc2 (V) Additional waves (V)
4 0.630 0.586 1.143 —
6 0.623 0.581 1.110 —
16 0.807 0.761 1.348 1.993, 2.436
25 0.286 0.244 0.930 —
26 0.291 0.252 0.940 —
28 0.511 0.467 0.799 0.965, 1.311
30 0.521 0.475 0.648 0.999, 1.216
31 0.535 0.472 1.055 —
32 0.515 0.454 0.950 —
33 0.510 0.464 0.925 —
34 0.493 0.444 1.001 1.441
35 0.506 0.457 0.935 —
Figure 2. ORTEP-3 projection of compound 38 showing atom labeling and
displacement ellipsoids drawn at the 50% probability level.
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ical reduction behavior of each compound. Initial cathodic and
anodic peak currents were also determined for each compound.Table 2
Crystal data and structure reﬁnement for compound 38
Empirical formula C22H
Formula weight 386
Temperature 150(
Wavelength 0.71
Crystal system, space group Mon
Unit cell dimensions a = 5
b = 1
c = 1
Volume 921
Z, Calculated density 2, 1.
Absorption coefﬁcient 0.09
F(000) 404
Crystal size 0.08
Theta range for data collection 2.28
Limiting indices 7<
Reﬂections collected
Independent reﬂections
478
334
Completeness to theta = 26.32 99.9
Absorption correction Sem
Max. and min. transmission 1 an
Reﬁnement method Full-
Data/restraints/parameters 334
Goodness-of-ﬁt on F2 1.10
Final R ÿ indices [I >2r(I)] R1 =
R indices (all data) R1 =
Largest diff. peak and hole 0.29It was not feasible to study all of the quinones in the present
work. Representative compounds were selected to cover each of
the structural classes (Schemes 2–4).
As has been noted, the compounds described here can be di-
vided among three structural classes: dihydropyran-para-naphtho-
quinones (4 and 6), para-naphthoquinone derivatives (16, 25 and
26), and ortho-dihydrofuranones (28, 30–35).
Figure 1 shows the cyclic voltammograms of compounds 4, 6,
16, 25, 26, 28, and 30–35. All of the quinones exhibited quasi-
reversible reduction behavior (Fig. 1). The major electrochemical
parameters for each compound are listed in Table 1.
The relative ease of reduction among the compounds was estab-
lished by comparison of their ﬁrst reduction potentials
(Epc1, Table 1, column 2). The relative reduction potential of the
compounds is as follows: 25 > 26 > 34 > 35 > 33 > 28  32  30 >
31 > 6  4 > 16.
The values of Eredox were obtained from the equation (Epc1 +
Epa1)/2 and are shown in Table 1. As was expected for quinonoid
compounds, the overall CV proﬁles are similar to those reported
for other quinones. The characteristic proﬁle shows two couples
of cathodic and anodic peaks, represented by diffusional (EpIc a
m1/2) quasi-reversible systems.19b,c The ﬁrst pair is related to the
formation of a radical anion (SQ⁄⁄-, Eq. (1)). The second pair of
peaks is broader and ill-deﬁned, as has been observed previ-
ously.19b This broadening may be due to possible disproportion-
ation or comproportionation reactions.19b
As shown in Table 1, compounds 25 and 26 (Fig. 1d and e) are
most easily reduced. The direct attachment of the electron-with-
drawing triazole affects the electrochemical behavior of the para-
quinones in a way that facilitates electron transfer. On the other
hand, the presence of an electron-donating amine group increases
the barrier to reduction of compound 16 (Fig. 1c). This compound
presents two additional waves at more negative potentials (Epc3
and Epc4, Fig. 1c, Table 1, column 4). A full description of the
electrodic mechanism is beyond the scope of the present paper
and will be described elsewhere. It is noticeable that nor-b-lapach-
one ortho-quinones derivatives (31–35, Fig. 1h–l) are more easily
reduced than are the a-lapachone-derived 1,2,3-triazoles (4 and
6, Fig. 1a and b), as has been shown previously.19b The CV of com-
pound 34, which shows the lowest negative potential in this series,18N4O3
.41
2) K
073 Å
oclinic, P21
.6099(2) Å a = 90
1.3548(5) Å b = 96.641(4)
4.5658(7) Å c = 90
.61(7) Å3
392 mg/m3
5 mm1
7  0.170  0.188 mm3
–29.42
=h<=7, 14<=k<=14, 19<=l<=18
9
6 [R(int) = 0.0275]
5%
i-empirical from equivalents
d 0.93
matrix least-squares on F2
6/1/272
7
0.0465, wR2 = 0.1163
0.0598, wR2 = 0.1342
2 and 0.315 e Å3
Table 3
Intermolecular interaction parameters (A, ) for compound 38
A-H  B d(A-B) d(A-H) d(H  A) <(DHA)
C181-H181  N3 3.364(4) 0.963(3) 2.665(2) 129.8(2)
C192-H192  N2 3.297(4) 0.977(3) 2.588(2) 129.51(19)
C13-H13  O2 3.477(3) 0.984(3) 2.527(2) 162.24(19)
Symmetry operators: (1) x, 0.5 + y, 2  z; (2) 1  x, 0.5 + y, 2  z; (3) 1 + x, y, z.
Table 4
Activity of compounds against the trypomastigote form of T. cruzi
Compound IC50/24 ha (lM)
Lapachol (1)b 410.8 ± 53.5
a-Lapachone (2)b >4800
4-Azido-a-lapachone (3) 318.2 ± 31.8
4 >2000
5 >4000
6 >500
Nor-a-lapachone (7)c >4800
3-Azido-nor-a-lapachone (8)c 179.3 ± 12.0
9 >1500
10 >2000
11 >4000
12 >4000
13 >4000
14 >4000
15 >4000
16 >4000
17 >4000
18 >4000
19 >4000
19 >4000
20 >4000
21 >4000
22 >4000
23 >4000
24 >4000
25d 10.9 ± 1.8
26d 45.8 ± 5.1
3-Azido-nor-b-lapachone (27)c 50.2 ± 3.8
28 80.8 ± 6.5
29 6.8 ± 0.7
30 8.2 ± 0.7
31a 17.3 ± 2.0
32c 20.8 ± 1.9
33c 359.2 ± 11.1
34c 21.8 ± 3.1
35c 39.6 ± 4.0
36 >4000
37 >1500
38 >3200
Benznidazolec 103.6 ± 0.6
Crystal violetc 536.0 ± 3.0
a Mean ± SD of at least three independent experiments.
b Ref. 18d.
c Ref. 16a.
d Ref. 16d.
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electron-withdrawing nitro group (Fig. 1k). The behavior of this
compound is characterized by three waves. The ﬁrst wave arises
from single electron transfer to the quinone system. The second
is attributable to a combined system, with two close electron
transfers: one to the semiquinone and the other to the nitroaro-
matic group, generating a nitro radical anion. The third wave is re-
lated to further reduction of the nitroaromatic system.
The presence of two quinone systems in 28 and 30
(Fig. 1f and g) leads to CV curves displaying considerably more
complex features. These curves show at least four cathodic waves
and corresponding anodic waves. It is clear from comparison with
the CV of compound 16 that the ﬁrst wave is related to the
reduction of the ortho-quinone.
2.3. X-ray analysis
The Ortep-3 diagram of 38 is shown in Figure 2, and Table 2
lists the major crystallographic parameters. Compound 38 crys-
tallizes in the non-centrosymmetric space group P21, with one
molecule in the asymmetric unit. The bond lengths and angles
are in good agreement with expected values, based on each
atomic type. Although the statistical and structural parameters
indicate that the structure is well solved, the Flack parameter
indicates that the absolute structure cannot be resolved from
this analysis. The crystal structure reveals one intramolecular
hydrogen bond (O1–H10  O2) that forms a six-membered ring.
Three main planes may be deﬁned through the molecule. Plane
1 is formed by the quinoidal ring (atoms C1 to C10, as O1, O2
and N4). It is interesting to note that atoms C11 and O3 of the
furan ring are close to plane 1 (distances equal to 0.059(4) ÅA
0
0.044(4) A), while atom C12 is more distant from this plane
(0.238(5) ÅA
0
). Plane 2 is formed by atoms N1, N2, N3, C13 and
C14. Nitrogen N1 of this plane is bonded to the chiral C11 atom
of plane 1. The distance between C11 and plane 2 is equal to
0.018(5) ÅA
0
, indicating that these atoms belong to both planes.
Plane 3 is deﬁned through the benzene ring (atoms C15–C20).
The angle between planes 1 and 2 is equal to 85.75(7), while
the angle between planes 2 and 3 is equal to 18.91(18). This
suggests that the phenyl ring and the triazole group are approx-
imately coplanar. The crystal packing is stabilized by intermolec-
ular C–H  N and C–H  O interactions, involving atoms C13, N2
and N3 of the triazole ring (Table 3).
2.4. Biological activity
We have recently described the introduction of 1,2,3-triazole
and arylamino groups into naphthoquinoidal structures; some of
these substances were identiﬁed as potent trypanocidal com-
pounds.16 In that work, we demonstrated that 1,4-naphthoqui-
nones and b-lapachones derivatized with a 1,2,3-triazole had
efﬁcacy as novel trypanocidal compounds.
In the present study, we have evaluated four classes of com-
pounds for activity against T. cruzi. These include a-(4–6) and
nor-a-lapachone-derived 1,2,3-triazoles (9–12), aminomethyl-
naphthoquinones conjugated to N-phthalimide via triazolelinkers (13–22), nor-b-lapachone-derived 1,2,3-triazole-conjugated
aminoquinones (28–30) and derivatives of nor-b-lapachone bearing
phenazine and oxime moieties (36–38). Previously published data
are included in Table 4 and the associated footnote to enable
comparison.16a,d
The ﬁrst class of compounds, a-lapachones linked to 1,2,3-tria-
zoles (para-quinones, Scheme 2), was synthesized from a-lapach-
one (2) and nor-a-lapachone (7). We sought to evaluate the
effect of the 1,2,3-triazole ring on the trypanocidal activity of these
compounds. This strategy had previously been shown to be effec-
tive for derivatives of nor-b-lapachone (ortho-quinones). Unfortu-
nately, compounds 4–6 and 9–12 were inactive against
trypomastigote forms of T. cruzi, with IC50/24 h values greater than
500 lM for all derivatives (Table 4).
The hybrids of 1,4-naphthoquinone and N-phthalimide (13–22)
were prepared from brominated, chlorinated or unsubstituted
quinones with spacers of one, two or three carbon atoms between
the 1,2,3-triazole ring and the N-phthalimido group (Scheme 3).
Compounds 13–22 were inactive against T. cruzi, as all showed
IC50/24 h values greater than 4000 lM. Compounds 23 and 24
were also inactive (Table 4).
The last class of naphthoquinoidal compounds described herein
was designed to couple ortho-quinone to para-quinoidal structures
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Figure 3. Graph correlating the values of Epc1 of each quinone with its trypan-
ocidal activity (bloodstream trypomastigote forms), represented by IC50/24 h (lM).
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yellow and orange crystalline solids. Our approach proved to be
effective, and 28, 29 and 30 showed IC50/24 h values of 80.8, 6.8
and 8.2 lM, respectively (Table 4). The compounds 29 and 30were
about 15 times more potent than benznidazole, the drug used for
the treatment of Chagas disease. A hypothesis for the potent try-
panocidal activity is that the union of ortho- and para-quinoidal
moieties can generate high concentrations of reactive oxygen spe-
cies, in general related to activity of this class of compounds. Anal-
ysis of the toxicity to heart muscle cells gave the LC50/24 h values
of <125, 63.1 and 281.6 lM for 28, 29 and 30, respectively, corre-
sponding to selectivity indexes (SI) of <1.5, 9.3 and 34.3. As precon-
ized in the workshop ‘Experimental Models in Drug Screening and
Development for Chagas Disease’ organized by Fiocruz and Drugs
for Neglected Diseases Initiative (DNDi)32 establishing a protocol
for drug screening, compound 30 will be submitted to in vivo
experiments using T. cruzi-infected mice. These results highlight
the potential of these compounds as novel trypanocidal agents.
To evaluate the importance of redox centers primarily as releas-
ers of ROS, we prepared a series of compounds by modifying the
scaffold of the previously described trypanocidal nor-b-lapachone
derivative 31 (Scheme 5).16a Compounds 36–38 were evaluated
against trypomastigote forms of T. cruzi, but none were found to
be active (Table 4).
A comparison of the data in Tables 1 and 4 (Fig. 3) reveals a
trend: more electrophilic quinones, that is, those with less negative
values for Epc1, (Epc1 >0.6 V vs Ag/AgCl, Table 1) were more po-
tent trypanocidal compounds. Compound 33 was the lone excep-
tion to this trend.
Electrochemical experiments (analytical and preparative) and
electrochemical (thermodynamic and kinetic) parameters are
useful in biomedical chemistry, particularly in elucidating the
mechanisms of biological electron-transfer processes. Such anal-
yses can be useful in the design of putatively bioactive lead
compounds for which the mechanism of action is based on redox
reactions leading to oxidative stress.21a
3. Conclusions
We evaluated twenty-six compounds, and three were identiﬁed
as potent trypanocidal agents. These compounds were more active
than the anti-T. cruzi drug benznidazole, the current therapeutic
standard. As compound 30 was 12-fold more active than benzni-
dazole, it is a promising candidate for further investigation. The
electrochemical properties of selected compounds were studied,
and important correlations were found with trypanocidal activity.4. Experimental section
4.1. Chemistry
Melting points were obtained on Thomas Hoover and are
uncorrected. Analytical grade solvents were used. Column chroma-
tography was performed on silica gel (SiliaFlash G60 UltraPure—
60–200 lm, 60 Å). Infrared spectra were recorded on an FTIR
Spectrometer IR Prestige-21—Shimadzu. 1H and 13C NMR were
recorded at room temperature using a Bruker AVANCE DRX200,
Varian Mercury 300 and Varian Mercury 400 MHz, in the solvents
indicated, with TMS as internal reference. Chemical shifts (d) are
given in ppm and coupling constants (J) in Hertz. High resolution
mass spectra (electrospray ionization) were obtained using a
MicroTOFIc—BrukerDaltonics. Elemental analysis was performed
using a CE Instruments (Thermo-Fisher) EA 1110 CHNS-O elemen-
tal analyzer. All the compounds were nominated using the
program CS ChemDraw Ultra version 10.0.
4.2. General procedure for the synthesis of compounds 17–24
Method A: In a ﬂask containing 3 mL acetonitrile, it was added
0.5 mmol of the appropriate azides, followed by 0.6 mmol of the
appropriate alkynes and ﬁnally 11 mg (0.06 mmol) of copper(I) io-
dide. The reaction was left under magnetic stirring at 28 C under
argon atmosphere, for a reaction time ranging from 19 to 24 h.
The end of the reaction was monitored by TLC with dichlorometh-
ane as eluent. The solvent was then removed under reduced
pressure and the reaction mixture was puriﬁed on a silica gel
column as a gradient mixture of hexane/ethyl acetate or dichloro-
methane/ethyl acetate with increasing polarity.Method B: In a ﬂask
containing 2 mL of DMF, it was added 0.5 mmol of the appropriate
azides, followed by 0.6 mmol of the appropriate alkynes, 11 mg
(0.06 mmol) of copper(I) iodide and ﬁnally 1 drop of Et3N. The
reaction was left under ultrasound energy at 28 C, during
30 min. After the end of the reaction monitored by TLC with
dichloromethane, the mixture was puriﬁed as described in method
A.Method C: The same procedures described in Method A, but 2 mL
DMF, one drop Et3N were added and the reaction was left under
magnetic stirring for 60 min as monitored by TLC. Method D: The
same procedures described in method A, 2 mL of DMF were added,
and the reaction was left under magnetic stirring for 60 min as
monitored by TLC.4.2.1. 2-((4-(((3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)isoindoline-1,3-
dione (17)
Using method D, compound 17 was obtained as an orange solid
(200 mg, 0.44 mmol, 87% yield); mp 170–172 C. IR mmax (cm1,
KBr): 3324, 3140, 2955, 1775, 1712, 1672, 1605, 1573, 1507,
1403, 1363, 1330, 1293, 1136, 1048, 953, 717. 1H NMR
(400 MHz, CDCl3) d: 8.12 (dd, 1H, J = 1.2 and 8.0 Hz), 8.01 (dd,
1H, J = 1.2 and 8.0 Hz), 7.91–7.89 (m, 3H), 7.78–7.76 (m, 2H),
7.70 (td, 1H, J = 1.6 and 7.3 Hz), 7.61 (td, 1H, J = 1.6 and 7.3 Hz),
6.41 (br s, 1H, NH), 6.20 (s, 2H), 5.14 (d, 2H, J = 6.4 Hz). 13C NMR
(100 MHz, CDCl3) d: 177.6, 174.1, 163.8, 142.4, 141.4, 132.4,
132.1, 132.0, 128.8, 127.4, 124.2, 124.1, 121.6, 121.4, 120.5,
120.3, 47.2, 37.6. Anal. Calcd for C22H14ClN5O4 0.3  H2O: C,
58.30; H, 3.25; N, 15.45. Found: C, 58.48; H, 3.21; N, 15.24.
4.2.2. 2-(2-(4-(((3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethyl)isoindoline-1,3-
dione (18)
Using method D, compound 18 was obtained as a red solid
(200 mg, 0.44 mmol, 71% yield); mp 197–199 C. IR mmax (cm1,
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1356, 1298, 1139, 1049, 943, 720. 1H NMR (400 MHz, CDCl3) d:
8.15 (d, 1H, J = 7.6 Hz), 8.04 (d, 1H, J = 7.6 Hz), 7.79–7.61 (m, 7H),
6.41 (br s, 1H, NH), 5.13 (d, 2H, J = 5.6 Hz), 4.69 (t, 2H, J = 6.4 Hz),
4.15 (t, 2H, J = 6.0 Hz). 13C NMR (100 MHz, CDCl3) d: 180.3, 167.5,
134.8, 134.3, 132.6, 131.7, 126.8, 123.6, 48.2, 40.3, 37.7. Anal. Calcd
for C23H16ClN5O4 0.35  H2O: C, 59.01; H, 3.49; N, 15.16. Found: C,
59.38; H, 3.64; N, 14.56.
4.2.3. 2-(3-(4-(((3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)propyl)isoindoline-1,3-
dione (19)
Using method D, compound 19 was obtained as a red solid
(200 mg, 0.44 mmol, 94% yield); mp 179–181 C. IR mmax (cm1,
KBr): 3313, 3141, 1774, 1712, 1678, 1602, 1571, 1525, 1435,
1293, 1139, 1049, 716. 1H NMR (400 MHz, acetone-d6) d: 7.93–
7.60 (m, 2H), 7.70–7.61 (m, 7H), 6.94 (br s, 1H, NH), 5.01 (d, 2H,
J = 5.9 Hz), 4.37 (t, 2H, J = 7.0 Hz), 3.59 (t, 2H, J = 6.7 Hz), 2.18 (qt,
2H, J = 7.0 Hz). 13C NMR (100 MHz, acetone-d6) d: 181.7, 175.2,
167.3, 143.9, 134.1, 133.4, 131.9, 125.9, 122.2, 121.9, 46.9, 39.6,
34.3. Anal. Calcd for C24H18ClN5O4: C, 60.57; H, 3.81; N, 14.72.
Found: C, 60.38; H, 3.69; N, 14.45.
4.2.4. 2-((4-(((3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)isoindoline-1,3-
dione (20)
Using method C, compound 20 was obtained as a red solid
(200 mg, 0.40 mmol, 88% yield); mp 155–157 C. IR mmax (cm1,
KBr): 3250, 3123, 1778, 1725, 1675, 1596, 1567, 1401, 1361,
1329, 1292, 1132, 1045, 783, 737. 1H NMR (400 MHz, acetone-d6)
d: 8.13 (s, 1H), 8.07–7.65 (m, 8H), 7.02 (br s, 1H, NH), 6.25 (s,
2H), 5.20 (d, 2H, J = 5.1 Hz). 13C NMR (100 MHz, acetone-d6) d:
179.4, 174.9, 165.9, 144.6, 134.4, 134.2, 131.9, 131.1, 130.9,
125.9, 122.9, 122.6, 49.4, 39.8. Anal. Calcd for C22H14BrN5O4: C,
53.68; H, 2.87; N, 14.23. Found: C, 53.62; H, 2.97; N, 13.86.
4.2.5. 2-(2-(4-(((3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethyl)isoindoline-1,3-
dione (21)
Using method A, compound 21 was obtained as a red solid
(200 mg, 0.40 mmol, 90% yield); mp 169–170 C. IR mmax (cm1,
KBr): 3314, 3274, 3129, 1772, 1714, 1591, 1565, 1397, 1286,
1124, 1024, 939, 722. 1H NMR (300 MHz, CDCl3) d: 8.14 (dd, 1H,
J = 1.5 and 7.5 Hz), 8.03 (dd, 1H, J = 1.5 and 7.5 Hz), 7.79–7.77 (m,
2H), 7.76 (s, 1H), 7.72–7.61 (m, 4H), 6.48 (br s, 1H, NH), 5.14 (br
s, 2H), 4.70 (t, 2H, J = 5.9 Hz), 4.15 (t, 2H, J = 5.9 Hz). 13C NMR
(100 MHz, CDCl3) d: 180.0, 176.5, 167.6, 146.2, 144.8, 134.7,
134.3, 132.5, 132.2, 131.6, 130.0, 127.0, 126.9, 123.6, 122.5, 48.2,
40.6, 37.7. Anal. Calcd for C23H16BrN5O4: C, 54.56; H, 3.19; N,
13.85. Found: C, 54.46; N, 3.58; H, 13.48.
4.2.6. 2-(3-(4-(((3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)propyl)isoindoline-1,3-
dione (22)
Using method C, compound 22 was obtained as a red solid
(200 mg, 0.40 mmol, 70% yield); mp 168–170 C. IR mmax (cm1,
KBr): 3219, 3137, 1770, 1711, 1680, 1600, 1566, 1389, 1290,
1131, 1054, 715. 1H NMR (300 MHz, CDCl3) d: 8.13 (dd, 1H,
J = 0.9 and 6.9 Hz), 8.04 (dd, 1H, J = 1.2 and 7.5 Hz), 7.85–7.80 (m,
3H), 7.76–7.60 (m, 4H), 6.57 (br s, 1H, NH), 5.17 (d, 2H,
J = 5.1 Hz), 4.41 (t, 2H, J = 6.6 Hz), 3.74 (t, 2H, J = 6.9 Hz), 2.35 (qt,
2H, J = 6.3 Hz). 13C NMR (100 MHz, CDCl3) d: 180.2, 176.8, 168.6,
146.5, 135.0, 134.5, 132.8, 132.4, 132.1, 130.2, 127.3, 127.2,
123.7, 48.2, 40.9, 35.2, 29.6. Anal. Calcd for C24H18BrN5O4: C,
55.40, H, 3.49, N, 13.46. Found: C, 55.61, H, 3.82, N, 13.37.4.2.7. 2-(((1-(3-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)
amino)naphthalene-1,4-dione (23)
Using method B, compound 23 was obtained as an orange solid
(200 mg, 0.54 mmol, 78% yield); mp 234–235 C. IR mmax (cm1,
KBr): 3298, 3132, 1673, 1640, 1590, 1526, 1350, 1260, 1046, 804,
721. 1H NMR (400 MHz, DMSO-d6) d: 8.94 (s, 1H), 8.68 (br s, 1H,
NH), 8.38 (dd, 1H, J = 2.0 and 8.0 Hz), 8.30 (dd, 1H, J = 2.0 and
8.4 Hz), 8.02–7.71 (m, 6H), 5.80 (s, 1H), 4.62 (d, 2H, J = 4.8 Hz).
13C NMR (100 MHz, DMSO-d6) d: 181.4, 181.3, 148.4, 148.1,
144.7, 137.0, 134.6, 132.9, 132.1, 131.3, 130.3, 125.9, 125.7,
125.2, 122.8, 121.7, 114.5, 100.6, 37.3. Anal. Calcd for
C19H13N5O4: C, 60.80; H, 3.49; N, 18.66. Found: C, 60.83, H, 3.84,
N, 18.86.
4.2.8. 2-Bromo-3-(((1-(3-nitrophenyl)-1H-1,2,3-triazol-4-
yl)methyl)amino)naphthalene-1,4-dione (24)
Using method A, compound 24 was obtained as an orange solid
(200 mg, 0.44 mmol, 86% yield); mp 175–176 C. IR mmax (cm1,
KBr): 3298, 3132, 1673, 1640, 1590, 1526, 1350, 1260, 1046, 804,
721. 1H NMR (400 MHz, DMSO-d6) d: 8.91 (s, 1H), 8.68 (br s, 1H,
NH), 8.37 (d, 1H, J = 8.0 Hz), 8.29 (d, 1H, J = 8.4 Hz), 7.99 (d, 1H,
J = 7.6 Hz), 7.88–7.74 (m, 5H), 5.16 (d, 2H, J = 6.4 Hz). 13C NMR
(100 MHz, DMSO-d6) d: 179.6, 175.3, 148.4, 147.4, 147.0, 137.1,
134.6, 132.6, 131.4, 131.3, 130.1, 126.5, 126.0, 125.8, 122.8,
121.3, 114.5. Anal. Calcd for C19H12BrN5O4, 0.45  H2O: C, 49.36;
H, 2.81; N, 15.15. Found: C, 49.72; H, 3.18, N, 14.78.
4.2.9. 3-(4-(((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)
methyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethyl-2,3-
dihydronaphtho[1,2-b]furan-4,5-dione (28)
Using method A, compound 28 was obtained as a yellow solid
(220 mg, 0.7 mmol, 65% yield); mp 218–220 C. IR mmax (cm1,
KBr): 3352 (NH), 1671 (C@O), 1654 (C@O), 1605 (C@O), 1565
(C@O). 1H NMR (400 MHz, DMSO-d6) d: 8.26 (s, 1H), 8.02 (d, 1H,
J = 7.34 Hz), 7.97–7.93 (m, 1H), 7.92–7.86 (m, 2H), 7.84–7.76 (m,
3H), 7.76–7.67 (m, 2H), 6.01 (s, 1H), 5.68 (s, 1H), 4.45 (d, 2H,
J = 5.98 Hz), 1.65 (s, 3H), 0.97 (s, 3H). 13C NMR (100 MHz, DMSO-
d6) d: 181.9, 180.1, 174.9, 170.1, 148.6, 143.4, 135.2, 135.1, 133.4,
133.3, 132.7, 132.1, 130.7, 129.1, 126.9, 126.3, 125.7, 125.4,
123.9, 111.6, 101.0, 95.6, 66.5, 38.0, 27.3, 21.0. EI-HRMS (m/z)
[M+H]+: 481.1424. Calcd for [C27H20N4O5H]+: 481.1512.
4.2.10. 3-(4-(((3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethyl-2,3-
dihydronaphtho[1,2-b]furan-4,5-dione (29)
Using method A, compound 29 was obtained as an orange solid
196 mg, 0.5 mmol, 70% yield); mp 167–168 C. IR mmax (cm1, KBr):
3348 (NH), 1671 (C@O), 1651 (C@O), 1608 (C@O), 1565 (C@O). 1H
NMR (400 MHz, DMSO-d6) d: 8.21 (s, 1H), 8.01 (d, 1H, J = 7.26 Hz),
7.94–7.88 (m, 2H), 7.84–7.75 (m, 3H), 7.74–7.68 (m, 3H), 5.99 (s,
1H), 4.99 (d, 2H, J = 6.36 Hz), 1.65 (s, 3H), 0.97 (s, 3H). 13C NMR
(100 MHz, DMSO-d6) d: 180.1, 175.8, 174.9, 170.2, 168.7, 147.2,
145.6 135.1, 133.4, 133.1, 132.1, 131.8, 130.4, 129.1, 127.0, 126.4,
125.4, 123.4, 123.3, 111.7, 95.6, 40.3, 27.3, 21.0. EI-HRMS (m/z)
[M+H]+: 559.0532. Calcd for [C27H19BrN4O5H]+: 559.0617.
4.2.11. 3-(4-(((3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)amino)methyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethyl-2,3-
dihydronaphtho[1,2-b]furan-4,5-dione (30)
Using method A, compound 30 was obtained as an orange solid
(211 mg, 0.5 mmol, 82% yield); mp 194–195 C. IR mmax (cm1,
KBr): 3355 (NH), 1671 (C@O), 1615 (C@O), 1605 (C@O), 1565
(C@O). 1H NMR (400 MHz, DMSO-d6) d: 8.24 (s, 1H), 8.02 (d, 1H,
J = 6.94 Hz), 7.95–7.90 (m, 2H), 7.86–7.76 (m, 4H), 7.76–7.70 (m,
2H), 6.02 (s, 1H), 4.98 (d, 2H, J = 6.65 Hz), 1.67 (s, 3H), 0.99 (s,
3H). 13C NMR (100 MHz, DMSO-d6) d: 180.4, 180.2, 175.9, 174.9,
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127.0, 126.9, 126.2, 125.4, 123.3, 111.7, 95.6, 66.5, 40.3, 27.3, 21.0.
EI-HRMS (m/z) [M+H]+: 515.1022. Calcd for [C27H19ClN4O5H]+:
515.1122.
4.2.12. 2,2-Dimethyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-2,3-
dihydrobenzo[f]furo[2,3-h]quinoxaline (36)
Nor-b-lapachone-based 1,2,3-triazole 31 (200 mg, 0.54 mmol)
was reacted with an excess of ethylenediamine (65 mg,
1.08 mmol) in 30 mL toluene. The reaction was stirred under reﬂux
in a Dean–Stark apparatus till the total consumption of the re-
agents as monitored by TLC. The solvent was evaporated under re-
duced pressure. The residue obtained was puriﬁed by column
chromatography on silica gel using an increasing polarity mixture
of hexane/ethyl acetate as eluent. Compound 36 was obtained as a
yellow solid (162 mg, 0.41 mmol, 77% yield, mp 235–238 C); IR
(KBr) 1595 (C@N), 1346 (C@C), 1070 (C–O), 767 (C–H) cm1. 1H
NMR (400 MHz, CDCl3) d: 9.28 (dd, 1H, J = 8.11 and 0.73 Hz), 8.74
(d, 1H, J = 2.16 Hz), 8.67 (d, 1H, J = 2.16 Hz), 8.25 (dd, 1H, J = 7.86
and 0.89 Hz), 7.95–7.84 (m, 2H), 7.71–7.67 (m, 2H), 7.34–7.28
(m, 2H), 7.26–7.22 (m, 2H), 6.63 (s, 1H), 1.80 (s, 3H), 1.34 (s, 3H).
13C NMR (100 MHz, CDCl3) d: 158.1, 146.1, 144.9, 141.0, 140.6,
138.2, 132.3, 130.3, 129.6, 129.5, 129.0, 128.8, 127.9, 125.2,
125.1, 124.7, 122.6, 122.5, 121.5, 109.8, 92.2, 67.7, 27.0, 21.1.
4.2.13. 2,2-Dimethyl-1-(4-phenyl-1H-1,2,3-triazol-1-yl)-1,2-
dihydrobenzo[a]furo[2,3-c]phenazine (37)
Nor-b-lapachone-based 1,2,3-triazole 31 (150 mg, 0.4 mmol)
was reacted with ortho-phenylenediamine (41 mg, 0.44 mmol)
and sodium acetate (62 mg, 0.76 mmol) in 25 mL glacial acetic
acid. The reaction was stirred at room temperature for 2 h. The
reaction was shed over cold water and the precipitate ﬁltered using
Buchner funnel. The solid obtained was puriﬁed by column chro-
matography on silica gel using an increasing polarity mixture of
hexane/ethyl acetate as eluent. Compound 37 was obtained as a
yellow solid (195 mg, 0.44 mmol, 82% yield, mp 224–227 C); IR
(KBr) 1597 (C@N), 1346 (C@C), 1049 (C–O), 763 (C–H) cm1.1H
NMR (400 MHz, CDCl3) d: 9.48 (d, 1H, J = 8.16 Hz), 8.31–8.26 (m,
1H), 8.26–8.21 (m, 1H), 8.06–8.01 (m, 1H), 7.98–7.93 (m, 1H),
7.92–7.86 (m, 1H), 7.78–7.72 (m, 2H), 7.70–7.66 (m, 2H), 7.31–
7.25 (m, 3H), 7.24–7.18 (m, 1H), 6.73 (s, 1H), 1.83 (s, 3H), 1.36 (s,
3H). 13C NMR (100 MHz, DMSO-d6) d: 160.2, 146.6, 142.2, 142.2,
141.1, 139.9, 132.9, 131.2, 131.0, 130.8, 130.5, 129.8, 129.6,
129.2, 129.1, 129.1, 128.6, 126.1, 125.5, 125.4, 124.3, 123.5,
121.8, 109.4, 93.1, 68.2, 27.5, 21.6.
4.2.14. (Z)-5-(Hydroxyimino)-2,2-dimethyl-3-(4-phenyl-1H-
1,2,3-triazol-1-yl)-2,3-dihydronaphtho[1,2-b]furan-4(5H)-one
(38)
Nor-b-lapachone-based 1,2,3-triazole 31 (200 mg, 0.54 mmol)
was reacted with hydroxylamine hydrochloride (120 mg,
1.68 mmol), sodium acetate (89 mg, 1.08 mmol) and catalytic tri-
ethylamine in 30 mL methanol. The reaction was stirred under re-
ﬂux overnight. The solvent was evaporated under reduced
pressure. The residue obtained was puriﬁed by column chromatog-
raphy on silica gel using an increasing polarity mixture of hexane/
ethyl acetate as eluent. Compound 38 was obtained as a yellow so-
lid (129 mg, 0.33 mmol, 62% yield, mp 222–225 C); IR (KBr) 3449
(OH), 1609 (C@O), 1524 (C@N), 972 (N–O) cm1. 1H NMR
(400 MHz, CDCl3) d: 8.41 (d, 1H, J = 8.09 Hz), 7.90 (d, 1H,
J = 7.75 Hz), 7.81 (d, 2H, J = 7.55 Hz), 7.73 (t, 1H, J = 7.67 Hz),
7.66–7.58 (m, 2H), 7.40 (t, 2H, J = 7.53 Hz), 7.32 (t, 1H,
J = 7.53 Hz), 6.10 (s, 1H), 1.78 (s, 3H), 1.27 (s, 3H). 13C NMR
(100 MHz, CDCl3) d: 202.5, 170.9, 149.4, 147.0, 131.7, 129.7,
129.6, 128.9, 128.8, 128.5, 126.2, 126.0, 125.1, 123.3, 123.3,
123.1, 118.7, 103.0, 89.9, 60.3, 23.1, 23.1.4.4. Trypanocidal activity
Stock solutions of the compounds were prepared in dimethyl
sulfoxide (DMSO), with the ﬁnal concentration of the latter in the
experiments never exceeding 0.1%. Preliminary experiments
showed that concentrations of up to 0.5%, DMSO have no deleteri-
ous effect on the parasites. Bloodstream trypomastigotes of the Y
strain were obtained at the peak of parasitaemia from infected al-
bino mice, isolated by differential centrifugation and resuspended
in Dulbecco’s modiﬁed Eagle medium (DME) to a parasite concen-
tration of 107 cells/mL in the presence of 10% of mouse blood. This
suspension (100 lL) was added in the same volume of each com-
pound previously prepared at twice the desired ﬁnal concentra-
tions. Cell counts were performed in Neubauer chamber and the
trypanocidal activity was expressed as IC50, corresponding to the
concentration that leads to lysis of 50% of the parasites.
4.5. Toxicity to heart muscle cells
The cytotoxicity assays were performed using primary cultures
of heart muscle cells (HMC). Brieﬂy, hearts of 18-day-old mouse
embryos were fragmented and dissociated with trypsin and colla-
genase in phosphate buffered saline (PBS pH 7.2), as previously
established.33 For these experiments, 6  104 cardiomyocytes in
100 mL of RPMI-1640 medium (pH 7.2) plus 10% foetal bovine ser-
um and 2 mM glutamine were added to each well of a 96-well
microtiter plate and incubated for 24 h at 37 C. The treatment
with 28–30 was performed in fresh supplemented medium with-
out phenol red (200 lL/well) for 24 h at 37 C. After this period,
110 lL of the medium was discarded and 10 lL of PrestoBlue
(Invitrogen) was added to complete the ﬁnal volume of 100 lL.
Thus, the plate was incubated for 5 h and the measurement was
performed at 570 and 600 nm, as recommended by the manufac-
turer. The results were expressed as the difference in the percent-
age of reduction between treated and untreated cells being the
LC50 value, corresponds to the concentration that leads to damage
of 50% of the mammalian cells.
4.6. X-ray analysis
X-ray data were collected at 150 K using MoKa (0.71073 Å) on
an Agilent—Gemini diffractometer equipped with a CCD area
detector. The CrysAlisPro software package34 was used for data col-
lection and data reduction. The data were corrected empirically for
absorption using spherical harmonics using the SCALE3 ABSPACK35
scaling algorithm. The structure was solved by direct methods
using SHELXS-9736 and reﬁned by full-matrix least squares on F2
using SHELXL-97.37 All non-hydrogen atoms were successfully re-
ﬁned using anisotropic displacement parameters. Hydrogen atoms
were found in the Fourier difference synthesis and ﬁxed. Crystallo-
graphic data for the structure were deposited in the Cambridge
Crystallographic Data Centre, with number CCDC 926844.
4.7. Electrochemical studies
Cyclic voltammetry (CV) experiments were performed with a
conventional undivided three electrode cell using an Autolab
PGSTAT-30 potentiostat (Echo Chemie, Utrecht, the Netherlands)
coupled to a microcomputer, interfaced by GPES 4.9 software.
Glassy carbon (GC) (diameter = 3 mm) as the working electrode,
a Pt wire as the counter electrode and the reference electrode an
Ag|AgCl, Cl (saturated) were used. The GC electrode was cleaned
up by polishing with alumina on a polishing felt (BAS polishing
kit). The solvent used in aprotic media studies, DMF, was distilled
under reduced pressure after stirring with anhydrous copper sul-
fate. In CV experiments, the scan rate varied from 10 to 500 mV
6348 E. B. T. Diogo et al. / Bioorg. Med. Chem. 21 (2013) 6337–6348s1. All experiments were conducted at room temperature (25 ±
2 C) and purging an inert gas (Argon). Electrochemical reduction
in aprotic media (DMF + TBAP 0.1 mol L1) was performed in the
absence of oxygen. Each compound (1  103 mol L1) was added
to the supporting electrolyte and the solution was deoxygenated
with argon before the measurements by cyclic voltammetry.
4.8. Statistical analysis
The comparison between the IC50 values for T. cruzi was per-
formed by ANOVA followed by the Student–Newman–Keuls and
Mann–Whitney tests (p <0.05).
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